Cargando…

Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway

Benign prostatic hyperplasia (BPH) is a pathological overgrowth of the human prostate. It may cause increased resistance to urine flow through the urethra and occasionally kidney damage, bladder stones and urinary tract infections, and therefore affect the quality of life. Qianliening capsule (QC) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	LIN, JIUMAO, ZHOU, JIANHENG, XU, WEI, ZHONG, XIAOYONG, HONG, ZHENFENG, PENG, JUN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671788/ https://www.ncbi.nlm.nih.gov/pubmed/23737867 http://dx.doi.org/10.3892/etm.2013.1008

Ejemplares similares

Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo
por: ZHONG, XIAOYONG, et al.
Publicado: (2015)

Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1α signaling pathway
por: LIN, JIUMAO, et al.
Publicado: (2014)

miRNA Regulation Network Analysis in Qianliening Capsule Treatment of Benign Prostatic Hyperplasia
por: Liu, Liya, et al.
Publicado: (2015)

The Effect of Xialiqi Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats
por: Cai, Hongcai, et al.
Publicado: (2018)

Mitochondrion-associated protein peroxiredoxin 3 promotes benign prostatic hyperplasia through autophagy suppression and pyroptosis activation
por: Jiang, Min-Yao, et al.
Publicado: (2017)

Suppression of benign prostate hyperplasia by Kaempferia parviflora rhizome
por: Murata, Kazuya, et al.
Publicado: (2013)

Benign Prostatic Hyperplasia
Publicado: (2015)

Possible clinical implications of prostate capsule thickness and glandular epithelial cell density in benign prostate hyperplasia
por: Holder, Katherine G., et al.
Publicado: (2021)

Antioxidant mitoquinone suppresses benign prostatic hyperplasia by regulating the AR–NLRP3 pathway
por: Jin, Bo-Ram, et al.
Publicado: (2023)

Anti-Inflammatory and Antioxidant Effects of Kelong-Capsule on Testosterone-Induced Benign Prostatic Hyperplasia in Rats
por: Zhang, Ling, et al.
Publicado: (2018)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Ellagic acid improves benign prostate hyperplasia by regulating androgen signaling and STAT3
por: Park, Woo Yong, et al.
Publicado: (2022)

An Update on the Outcomes of Patients Treated with Urolift for Benign Prostatic Hyperplasia
por: Loloi, Justin, et al.
Publicado: (2021)

Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia
por: Soliman, Mohamed G., et al.
Publicado: (2023)

Exploring the effects and mechanism of peony pollen in treating benign prostatic hyperplasia
por: Mu, Jun, et al.
Publicado: (2023)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Botulinum toxin and benign prostatic hyperplasia
por: Ng, Lay Guat
Publicado: (2018)

Solving the benign prostatic hyperplasia puzzle
por: Foo, Keong Tatt
Publicado: (2016)

Tissue microenvironment and benign prostatic hyperplasia
por: Wei, Xing, et al.
Publicado: (2019)

Prostatitis and benign prostatic hyperplasia: emerging infectious diseases?
por: Hennenfent, B
Publicado: (1997)

Zinc status in benign prostatic hyperplasia and prostate carcinoma
por: Wiwanitkit, Somsri, et al.
Publicado: (2012)

Linking Pre-Diabetes with Benign Prostate Hyperplasia. IGFBP-3: A Conductor of Benign Prostate Hyperplasia Development Orchestra?
por: Protopsaltis, Ioannis, et al.
Publicado: (2013)

Frozen-Thawed Sperm Analysis of Benign Prostatic Hyperplasia Dogs Treated With Finasteride
por: Flores, Renato Bueno, et al.
Publicado: (2022)

Soluble Guanylate Cyclase Activators to Treat Benign Prostatic Hyperplasia and associated LUTS
por: Kanai, A.J., et al.
Publicado: (2023)

Autophagy: a stumbling block of androgen inhibition to treat benign prostatic hyperplasia or prostate cancer
por: Zhang, Li, et al.
Publicado: (2016)

Morphological Changes of Benign Prostatic Hyperplasia in Culture
por: McMahon, M. J., et al.
Publicado: (1973)

Benign Prostatic Hyperplasia: from Bench to Clinic
por: Yoo, Tag Keun, et al.
Publicado: (2012)

VASTI THERAPY IN THE MANAGEMENT OF BENIGN PROSTATE HYPERPLASIA
por: Gupta, Shivaji, et al.
Publicado: (1997)

Current Laser Treatments for Benign Prostatic Hyperplasia
por: Son, Hwancheol, et al.
Publicado: (2010)

Benign prostatic hyperplasia: An overview of existing treatment
por: Dhingra, Neelima, et al.
Publicado: (2011)

Therapeutic options in the treatment of benign prostatic hyperplasia
por: Sandhu, Jaspreet S
Publicado: (2009)

Unsolved Issues in Managing Benign Prostatic Hyperplasia
por: Oh, Seung-June
Publicado: (2013)

Recent advances in treatment for Benign Prostatic Hyperplasia
por: van Rij, Simon, et al.
Publicado: (2015)

Diagnosis and treatment of benign prostate hyperplasia in Asia
por: Foo, Keong Tatt
Publicado: (2015)

Chromosomal aberrations in benign prostatic hyperplasia patients
por: Altok, Muammer, et al.
Publicado: (2016)

Fibronectin Pattern in Benign Hyperplasia and Cancer of the Prostate
por: Janković, Miroslava M., et al.
Publicado: (2008)

Metabolic syndrome and benign prostatic hyperplasia: An update
por: Ngai, Ho-Yin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7v0rcmmj4u81o14u0ibm55hql1